trial
as of 2026-07-01Clinical Study Of Schizophrenia in Both Men and Women
NCTId NCT00071747
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
176
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-08
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
GlaxoSmithKlineLead Sponsor
Sites
32 total
Little Rock, United StatesGarden Grove, United StatesLa Mesa, United StatesNational City, United StatesOceanside, United StatesRosemead, United StatesSan Diego, United StatesHartford, United StatesMaitland, United StatesNorth Miami, United StatesGranite City, United StatesGlen Burnie, United States
Facts & assertions
3 sourced
Enrollment
176
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication